Role of Metastatic Tumor Antigen-1 in Mammary Gland

转移性肿瘤抗原 1 在乳腺中的作用

基本信息

  • 批准号:
    6770171
  • 负责人:
  • 金额:
    $ 26.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-07-01 至 2007-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The ability of the mammary gland to undergo tumorigenesis is influenced by its normal development, including reproductive endocrine events. It is increasingly accepted that mammary gland development and tumorigenesis are fundamentally linked, and perturbations in the expression or function of steroidal coactivators and corepressors or its associated targets can contribute to the etiology of steroidal cancers. We propose here to investigate the influence of metastatic tumor antigen 1 (MTA1) on the reproductive biology of the mammary gland using in vitro, transgenic mouse models, and potential roles of MTA1 and a naturally occurring variant MTA1s in the early stages of breast cancer development. In addition, cyclin D1, an established oncogene and regulator of cell cycle progression, is a common downstream target of diverse upstream signals with a role in mammary gland development and tumorigenesis. Here we propose to investigate the influence of MTA1 and its downstream target cyclin D1 on the reproductive endocrinology and development of the mammary gland and early stages of breast tumor formation using novel model systems and human tumor specimens. The rationale for this proposal is based on Preliminary data by the PI showing that MTA1 promotes anchorage-independent growth, and upregulate cyclin D1 expression. A naturally occurring spliced variant known as "MTA1s" sequesters ER in the cytoplasm and stimulates anchorage-independent growth and tumorigenicity of breast cancer cells. MMTV-MTA1 transgene expression in a mouse model results in abnormal lateral branching and alveolar development, increased cyclin D1, and hyperplastic nodules in mammary glands from virgin females. We interpret these findings as suggesting that MTA1 may have significant roles in normal mammary development by controlling expression and consequently, functions of its putative target genes such as cyclin DI. Our working hypotheses are that MTA1 play regulatory functions during normal mammary gland development and that deregulation of the MTA1 may induce alterations including, upregulation of cyclin D1 pathway, involved in early stages of breast tumor development. The specific aims of this proposal are to study: (1) The influence of MTA1 transgene expression on the biology, development and tumorigenesis of mammary gland; (2) The mechanistic role of cyclin D1 in the action of MTA1 and whether these two proteins cooperate during mouse mammary gland tumorigenesis; (3) The expression characteristics of MTA1 and MTAls and cyclin D1 during multi-step pathogenesis of breast carcinoma and to evaluate its prognostic value in-patients with invasive breast cancer. An innovative aspect of this proposal is the use of novel models to gain insights about the roles of MTA1 and MTA1s as critical pathways in the reproductive biology of mammary gland in the pathophysiologically relevant experimental setting.
描述(由申请人提供):乳腺发生肿瘤的能力受其正常发育的影响,包括生殖内分泌事件。越来越多的人认为,乳腺发育和肿瘤发生具有根本的联系,类固醇共激活因子和辅抑制因子或其相关靶点的表达或功能的紊乱可能导致类固醇癌的病因。在此,我们拟通过体外、转基因小鼠模型研究转移性肿瘤抗原1 (MTA1)对乳腺生殖生物学的影响,以及MTA1和一种天然变异MTA1在乳腺癌早期发展中的潜在作用。此外,cyclin D1是一种已确定的癌基因和细胞周期进程的调节因子,是多种上游信号的常见下游靶标,在乳腺发育和肿瘤发生中发挥作用。本研究拟利用新型模型系统和人类肿瘤标本,研究MTA1及其下游靶点细胞周期蛋白D1对乳腺生殖内分泌、乳腺发育和乳腺肿瘤形成早期的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAKESH KUMAR其他文献

RAKESH KUMAR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAKESH KUMAR', 18)}}的其他基金

SERM Regulation of PAK Pathway in Endometrial Cancer
SERM 对子宫内膜癌 PAK 通路的调节
  • 批准号:
    7115811
  • 财政年份:
    2004
  • 资助金额:
    $ 26.88万
  • 项目类别:
SERM Regulation of PAK Pathway in Endometrial Cancer
SERM 对子宫内膜癌 PAK 通路的调节
  • 批准号:
    6929343
  • 财政年份:
    2004
  • 资助金额:
    $ 26.88万
  • 项目类别:
SERM Regulation of PAK Pathway in Endometrial Cancer
SERM 对子宫内膜癌 PAK 通路的调节
  • 批准号:
    6815054
  • 财政年份:
    2004
  • 资助金额:
    $ 26.88万
  • 项目类别:
SERM Regulation of PAK Pathway in Endometrial Cancer
SERM 对子宫内膜癌 PAK 通路的调节
  • 批准号:
    7228266
  • 财政年份:
    2004
  • 资助金额:
    $ 26.88万
  • 项目类别:
Role of Metastatic Tumor Antigen-1 in Mammary Gland
转移性肿瘤抗原 1 在乳腺中的作用
  • 批准号:
    6922026
  • 财政年份:
    2003
  • 资助金额:
    $ 26.88万
  • 项目类别:
Role of Metastatic Tumor Antigen-1 in Mammary Gland
转移性肿瘤抗原 1 在乳腺中的作用
  • 批准号:
    7075426
  • 财政年份:
    2003
  • 资助金额:
    $ 26.88万
  • 项目类别:
Role of Metastatic Tumor Antigen-1 in Mammary Gland
转移性肿瘤抗原 1 在乳腺中的作用
  • 批准号:
    6682968
  • 财政年份:
    2003
  • 资助金额:
    $ 26.88万
  • 项目类别:
Targeting Urokinase Pathway for Breast Cancer Therapy
针对乳腺癌治疗的尿激酶通路
  • 批准号:
    6645655
  • 财政年份:
    2001
  • 资助金额:
    $ 26.88万
  • 项目类别:
Pak1 in Mammary Gland Development and Carcinogenesis
Pak1 在乳腺发育和癌变中的作用
  • 批准号:
    6739038
  • 财政年份:
    2001
  • 资助金额:
    $ 26.88万
  • 项目类别:
Pak1 in Mammary Gland Development and Carcinogenesis
Pak1 在乳腺发育和癌变中的作用
  • 批准号:
    6515030
  • 财政年份:
    2001
  • 资助金额:
    $ 26.88万
  • 项目类别:

相似国自然基金

RKTG对ERK信号通路的调控和肿瘤生成的影响
  • 批准号:
    30830037
  • 批准年份:
    2008
  • 资助金额:
    190.0 万元
  • 项目类别:
    重点项目

相似海外基金

NIH resubmission Deyu Li - Etheno adductome and repair pathways
NIH 重新提交 Deyu Li - 乙烯加合组和修复途径
  • 批准号:
    10659931
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
Project 2: Ex Vivo Modeling and Analysis of Gastric Precancerous Lesions
项目2:胃癌前病变的离体建模与分析
  • 批准号:
    10715763
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
Investigating a new vulnerability in oral squamous cell carcinoma
研究口腔鳞状细胞癌的新脆弱性
  • 批准号:
    10714352
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
"Role of Amplified Protein Kinases in Head and Neck Squamous Cell Carcinoma Progression and Therapy Resistance."
“扩增的蛋白激酶在头颈鳞状细胞癌进展和治疗耐药中的作用。”
  • 批准号:
    10725901
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition
绘制头颈部癌前侵袭性疾病转变的免疫基因组驱动因素
  • 批准号:
    10770868
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
Identifying clinical and genetic factors for risk of multiple skin cancers in organ transplant recipients
确定器官移植受者患多种皮肤癌风险的临床和遗传因素
  • 批准号:
    10589535
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
Multiplex In-Solution Protein Array (MISPA) for high throughput, quantitative, early profiling of pathogen-induced head and neck
多重溶液内蛋白质芯片 (MISPA) 用于对病原体引起的头颈部进行高通量、定量、早期分析
  • 批准号:
    10713928
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
HMGB1 in EB-Associated Squamous Cell Carcinoma
EB 相关鳞状细胞癌中的 HMGB1
  • 批准号:
    10676346
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
A co-infection model for papillomavirus associated infections and cancers
乳头瘤病毒相关感染和癌症的共感染模型
  • 批准号:
    10667710
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
Patient oriented research and mentoring program in dermatologic diseases
以患者为中心的皮肤病研究和指导计划
  • 批准号:
    10685455
  • 财政年份:
    2023
  • 资助金额:
    $ 26.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了